HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Exploring Furlough Possibility If User Fee Bill Not Enacted In Time

Executive Summary

Furloughs would allow affected FDA staff to remain employed, while a layoffs would require affected workers to be rehired.

You may also be interested in...



US FDA User Fees: Lay-Off Notices Planned For Early September If Congress Doesn’t Pass Bill

The notices normally would go out on 1 August, but unspent user fee funds may be able to sustain work for a few weeks if the program expires.

Don’t Expect Abandonment Of US FDA User Fee Programs If They Sunset

Popular characteristics like goal dates are expected to remain in place if Congress does not renew the user fee programs by 1 October.

US FDA User Fee Legislation: Is Sen. Burr’s ‘Clean’ Bill A Lifeline – Or A Wrench In The Works?

Sen. Richard Burr introduces a reauthorization bill without any policy changes, even ones he previously endorsed, saying it’s the clearest path forward now.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152798

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel